Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268921 | 0.84 | PPARG (0.48) | PPARGCCR4CYP3A4LGALS8LGALS1 | |
| SCHEMBL1269970 | 0.84 | PPARG (0.45) | PPARGPTGDRPTGDR2CCR4CYP3A4 | |
| SCHEMBL1269442 | 0.72 | ALDH1A1 (0.50) | — | |
| SCHEMBL1269423 | 0.69 | ALDH1A1 (0.39) | PTGDRPTGDR2CCR4 | |
| SCHEMBL1268653 | 0.67 | SMN1; SMN2 (0.45) | PPARG | |
| SCHEMBL13790967 | 0.67 | L3MBTL1 (0.41) | — | |
| SCHEMBL1268646 | 0.65 | SLC40A1 (0.45) | PPARGPTGDRPTGDR2CCR4CYP3A4 | |
| SCHEMBL4771481 | 0.65 | L3MBTL1 (0.64) | CYP3A4 | |
| SCHEMBL4693338 | 0.62 | PPARG (0.56) | PPARGPTGDRPTGDR2CYP3A4 | |
| SCHEMBL1269561 | 0.62 | CCR4 (0.51) | PPARGCCR4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | PPARG 3/4885PTGDR 709/4885PTGDR2 649/4885 |
| US-20060084802-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | PPARG 3/4885PTGDR 709/4885PTGDR2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.